Voloridge Investment Management LLC Purchases Shares of 36,922 Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Voloridge Investment Management LLC purchased a new position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,922 shares of the biopharmaceutical company’s stock, valued at approximately $1,702,000. Voloridge Investment Management LLC owned approximately 0.06% of Agios Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AGIO. Quantamental Technologies LLC bought a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $28,000. Advisor Group Inc. grew its position in shares of Agios Pharmaceuticals by 33.1% in the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 297 shares during the period. ETF Managers Group LLC boosted its holdings in shares of Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 216 shares during the period. MML Investors Services LLC bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $255,000. Finally, Pacer Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $257,000. 98.77% of the stock is owned by hedge funds and other institutional investors.

NASDAQ AGIO traded down $1.47 on Monday, hitting $59.85. 251,061 shares of the company were exchanged, compared to its average volume of 461,625. The firm has a market cap of $3.53 billion, a PE ratio of -9.93 and a beta of 2.38. Agios Pharmaceuticals Inc has a 12 month low of $41.63 and a 12 month high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.65) by $0.07. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. The business had revenue of $30.00 million for the quarter, compared to analyst estimates of $19.98 million. During the same period in the prior year, the firm earned ($1.81) earnings per share. Agios Pharmaceuticals’s revenue was up 200.0% on a year-over-year basis. As a group, equities analysts anticipate that Agios Pharmaceuticals Inc will post -6.73 EPS for the current year.

Several brokerages recently commented on AGIO. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Svb Leerink upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Friday, February 15th. Finally, Piper Jaffray Companies lowered their price objective on shares of Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 14th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.86.

In other news, insider Scott Biller sold 9,000 shares of the stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $65.00, for a total value of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares in the company, valued at $1,838,005. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven L. Hoerter sold 10,000 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $67.01, for a total transaction of $670,100.00. Following the completion of the sale, the insider now owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,000 shares of company stock valued at $2,765,530. 3.02% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Voloridge Investment Management LLC Purchases Shares of 36,922 Agios Pharmaceuticals Inc (NASDAQ:AGIO)” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/voloridge-investment-management-llc-buys-new-stake-in-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Recommended Story: Asset Allocation and Your Retirement

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.